

# HIV PREVENTION LEARNING COMMUNITY



Bimonthly Newsletter

VOL. 5

OCTOBER 2022



## October Newsletter

### HUMAN MONKEYPOX (MPX) VIRUS TRANSMISSION

Many healthcare providers have **expressed concerns** about contracting Human MPX Virus (HMPXV) from patients. But how likely is this?

**HMPXV is not easily transmitted.** Human to human transmission occurs in three ways: direct contact with infected lesions or body fluids, contaminated fomites, or exposure to respiratory secretions.

However, the epidemiology of this current outbreak really highlights one transmission: **direct contact with infected lesions or body fluids.** While contaminated fomites and respiratory secretions are all reported and potential ways of transmission, that is not what we are seeing in this outbreak.

### SEPTEMBER LC RECAP

September's LC focused on **Human MPX Virus.** Dr. Zucker walked us through an early HMPXV case of his, and then addressed questions from our clinic attendees.

Some of the questions included were:

- Staff transmission concerns
- Avoiding inconclusive results
- Supportive care
- Vaccinations

We also spent some time talking about how to improve **clinical efficiency** with HMPXV testing and care. Are you interested in discussing what this may look like at your clinical setting? We're here to help!



## RESOURCES

- [September LC Slides](#)
- [CDC: HMPXV Information for Providers](#)
- [PPT: What Clinicians Need to Know](#)
- [MPX as an STI in New York State](#)
- [STI Treatment Guidelines Mobile App](#)

*What's next?*

## NEXT MONTH'S LC

### Details:

- November 29th at 12-1pm EST
- Topic: Express STI Care

### Reminder!

- Goal of LC is to have a discussion where clinics can learn from each other
- All participants keep cameras on. Need a webcam? Let us know!
- All participants contribute to the discussion
- 2-4 individuals per site participating



## DOXYPEP: WHAT DO YOU THINK?

DoxyPEP involves prescribing doxycycline for an individual to take 24-72 hours after sex as a way of preventing STIs. It is currently a hot topic of discussion!

Results from a [randomized open-label trial](#) were shared at the 2022 International AIDS Conference and also discussed at ID Week 2022. The trial found that doxyPEP significantly decreased infections of gonorrhea, chlamydia, and syphilis.

There is not yet official guidance on doxyPEP from the CDC. Many clinical concerns have been raised, including:

- How might this affect antibiotic resistance?
- Who could/should use doxyPEP?
- How could this impact health equity?
- How might this affect the process of diagnosing syphilis?

These questions and others have not yet been answered. What do you think about DoxyPEP?

Have a clinical question? Check out the clinical consultation line: [www.stdccn.org](http://www.stdccn.org)